Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genetron Holdings Limited Reveals Two Cancer Research Study Results At the Association for Molecular Pathology 2021 Annual Meeting

11/16/2021 | 05:00am EST

Genetron Holdings Limited announced the release of two research results from its Seq-MRD and FusionScan Plus product studies at the Association for Molecular Pathology 2021 annual meeting. Seq-MRD? detects minimal residual disease in B-lymphoid malignancies, while FusionScan Plus can simultaneously detect a wide range of gene mutations and fusions. The two studies verified the high sensitivity and high specificity of the two products, providing important insights for clinical diagnosis, medication guidance and monitoring of cancer relapses. After hematological cancer treatment, patients? bodies may sometimes not respond to treatment, or drug-resistant cancer cells may linger. Therefore, a considerable proportion of patients may still relapse. The number of these residual cancer cells are so small that they do not cause any recurring symptoms in the body, and it is difficult to detect them through traditional clinical methods. In order to accurately detect these residual cancer cells in patients after treatment, Seq-MRD scans for them through high throughput sequencing of immunoglobulin gene rearrangements. This product?s performance was validated by study #1064612. Genetron Health incorporated different types of samples in this study, including bone marrow from 56 B-cell malignancy patients, peripheral blood from 40 healthy donors, multiple myeloma cell line RPMI8226, and B-acute lymphoblastic leukemia cell line NALM6. Test performance parameters included accuracy, linearity, limit of detection, repeatability, limit of blank, and others. The study showed that high-throughput sequencing of B-cell receptor genes also exhibit higher sensitivity and specificity in the detection of MRD in lymphoid malignancies. Drugs targeting gene fusions have been used in clinical situations to treat cancer patients, and detecting gene fusions and drug resistant mutations can help better predict therapy effectiveness. High-throughput sequencing of integrated DNA and RNA is an ideal method to screen for gene mutations and fusions. However, current assays based on parallel detection of DNA and RNA can only detect specific gene mutations and fusions, and oftentimes need many different samples. Therefore, there is a strong clinical need for an assay that can simultaneously detect a wide range of gene mutations and fusions, and with lower threshold requirements. Genetron Health has developed a next generation sequencing assay, FusionScan Plus, which uses integrated DNA and RNA as a template for genetic alteration detection. Based on Genetron Health?s One Step Seq Method, FusionScan Plus covers 23 tumor-related genes and 37 fusion genes without a priori knowledge of 5' fusion partner. The study (#1062999) from examining 76 formalin-fixed paraffin-embedded tissue samples proved that FusionScan Plus demonstrated high accuracy in the simultaneous detection of gene mutations and fusions without a priori knowledge of 5' fusion partner. It can be used to detect drug sites for cancer patients, even with limited biopsy samples, and presents promising insights for clinical applications. The Association for Molecular Pathology was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,500+ members practice various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. Its members are pathologists, clinical laboratory directors, basic and translational scientists, technologists, and trainees that practice in a variety of settings, including academic and community medical centers, government, and industry. Through the efforts of its Board of Directors, Committees, Working Groups, and Members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high-quality, appropriate testing.

ę S&P Capital IQ 2021
01/10GENETRON : Health Reiterates Full Year 2021 Revenue Guidance - Form 6-K
01/10Genetron Health Reiterates Full Year 2021 Revenue Guidance
01/10Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance
2021Asian ADRs Decline in Wednesday Trading
2021BTIG Adjusts Genetron Holdings' Price Target to $17 From $21, Reiterates Buy Rating
2021Genetron Health's Social Contribution Campaign to Make Precision Medicine More Accessib..
2021Genetron Holdings Q3 Non-IFRS Loss Widens; Revenue Rises; Lowers 2021 Revenue Guidance
2021GENETRON : Health Announces Co-Development Agreement with AstraZeneca R&D China for Person..
2021Genetron Holdings Limited Reports Earnings Results for the Third Quarter and Nine Month..
2021GENETRON : 3Q21 Presentation
More news
Analyst Recommendations on GENETRON HOLDINGS LIMITED
More recommendations
Financials (USD)
Sales 2021 83,0 M - -
Net income 2021 -72,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -27,7x
Yield 2021 -
Capitalization 389 M 389 M -
Capi. / Sales 2021 4,69x
Capi. / Sales 2022 3,44x
Nbr of Employees 799
Free-Float -
Duration : Period :
Genetron Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENETRON HOLDINGS LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,38 $
Average target price 14,51 $
Spread / Average Target 231%
EPS Revisions
Managers and Directors
Si Zhen Wang Chief Executive Officer & Director
Ce Xu Chief Financial Officer
Wei-Wu He Chairman
Hai Yan Chief Scientific Officer & Director
Yu Chen Jiao Chief Technology Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689